ライフサイエンスコーパス: gastroesophageal reflux disease

1 st frequently performed surgical therapy for gastroesophageal reflux disease.

2 ved cells is a novel potential treatment for gastroesophageal reflux disease.

3 drome (IBS) frequently overlap with those of gastroesophageal reflux disease.

4 gents widely prescribed for the treatment of gastroesophageal reflux disease.

5 to evaluate for the presence of concomitant gastroesophageal reflux disease.

6 thereby conclusively distinguishing it from gastroesophageal reflux disease.

7 fundoplication is an effective treatment for gastroesophageal reflux disease.

8 increasingly recognized disease that mimics gastroesophageal reflux disease.

9 ders, including irritable bowel syndrome and gastroesophageal reflux disease.

10 ct patients from developing complications of gastroesophageal reflux disease.

11 itis is a new disease commonly confused with gastroesophageal reflux disease.

12 places esophageal squamous mucosa damaged by gastroesophageal reflux disease.

13 esophageal motor disorders and treatment of gastroesophageal reflux disease.

14 the association between BMI and symptoms of gastroesophageal reflux disease.

15 relation to the occurrence and management of gastroesophageal reflux disease.

16 and obese persons are at increased risk for gastroesophageal reflux disease.

17 actors usually indicative of severe types of gastroesophageal reflux disease.

18 d-mediated event and a reliable indicator of gastroesophageal reflux disease.

19 directions in the research and treatment of gastroesophageal reflux disease.

20 eading to duodenal ulcer, gastric ulcer, and gastroesophageal reflux disease.

21 ithout Barrett's esophagus or other types of gastroesophageal reflux disease.

22 ux surgery is performed for the treatment of gastroesophageal reflux disease.

23 esophagus in patients with mild-to-moderate gastroesophageal reflux disease.

24 ortened esophagus and stricture secondary to gastroesophageal reflux disease.

25 ormal-appearing cardia are manifestations of gastroesophageal reflux disease.

26 agus and adenocarcinoma are complications of gastroesophageal reflux disease.

27 astroesophageal junction and its relation to gastroesophageal reflux disease.

28 hageal junction are histologic indicators of gastroesophageal reflux disease.

29 that can occur in a subset of patients with gastroesophageal reflux disease.

30 c approach to the treatment of patients with gastroesophageal reflux disease.

31 progression of disease and complications of gastroesophageal reflux disease.

32 that is also found in obese patients without gastroesophageal reflux disease.

33 ery effective and long-lasting treatment for gastroesophageal reflux disease.

34 Obesity is associated with a risk of gastroesophageal reflux disease.

35 llow-up after ARS in pediatric patients with gastroesophageal reflux disease.

36 180-degree LAF for the surgical treatment of gastroesophageal reflux disease.

37 estive heart failure (1.35 [1.11-1.64]), and gastroesophageal reflux disease (1.39 [1.03-1.87]) were

38 ng bowel habit (15%), constipation (13%) and gastroesophageal reflux disease (12%).

39 lipidemia (24.5%), hypertension (21.9%), and gastroesophageal reflux disease (17.3%).

40 The presence of gastroesophageal reflux disease (26%), esophageal strict

41 ere rhinitis (84.0%), sinusitis (47.8%), and gastroesophageal reflux disease (46.3%).

42 ssociated with non-CF bronchiectasis include gastroesophageal reflux disease (47%), asthma (29%), and

43 structive sleep apnea may be associated with gastroesophageal reflux disease, a strong risk factor fo

44 allergic rhinitis, chronic rhinitis, asthma, gastroesophageal reflux disease, adenotonsillitis, sleep

45 : All patients should undergo monitoring for gastroesophageal reflux disease after POEM.

46 Risk factors evaluated included gastroesophageal reflux disease, alcohol consumption, sm

47 ibly due to increased abdominal pressure and gastroesophageal reflux disease, although this pathogeni

48 uency, severity, and duration of symptoms of gastroesophageal reflux disease among randomly selected

49 er improvement in quality of life related to gastroesophageal reflux disease and a 50% or greater red

50 rs to result in decreased prevalence of both gastroesophageal reflux disease and adenocarcinoma of th

51 and surgical techniques in the management of gastroesophageal reflux disease and constipation also ma

52 patterns from biopsies of patients with EoE, gastroesophageal reflux disease and controls.

53 ulosis is associated with conditions such as gastroesophageal reflux disease and diabetes mellitus, a

54 11,945 patients aged 18 years and older with gastroesophageal reflux disease and erosive esophagitis.

55 oplication was performed in 758 patients for gastroesophageal reflux disease and in 99 for paraesopha

56 allenges to diagnosis, including the role of gastroesophageal reflux disease and proton pump inhibito

57 75-year-old woman with a medical history of gastroesophageal reflux disease and type II diabetes pre

58 Despite their known association with gastroesophageal reflux disease and vagal nerve stimulat

59 g the role of nonacid reflux in cough due to gastroesophageal reflux disease, and 3) developing relia

60 cent had symptoms of dyspnea, 87 percent had gastroesophageal reflux disease, and 54 percent had nasa

61 lization for asthma, mechanical ventilation, gastroesophageal reflux disease, and aspiration or other

62 lation), and prior diagnoses (eg, pneumonia, gastroesophageal reflux disease, and other comorbidities

63 the individual to irritable bowel syndrome, gastroesophageal reflux disease, and peptic ulcer diseas

64 Laparoscopic procedures for gastroesophageal reflux disease appear to be as effectiv

65 e mechanisms involved in the pathogenesis of gastroesophageal reflux disease are complex and multifac

66 The high reoperation rate and incidence of gastroesophageal reflux disease are concerning.

67 ractical concepts regarding the treatment of gastroesophageal reflux disease are developed, based on

68 Typical symptoms of gastroesophageal reflux disease are heartburn and regurg

69 pump inhibitors and has focused attention on gastroesophageal reflux disease as a causative factor in

70 treat a variety of gastric disorders such as gastroesophageal reflux disease, autoimmune gastritis, g

71 factors for EAC have been identified-mainly gastroesophageal reflux disease, Barrett's esophagus, ob

72 We prospectively assessed 100 patients with gastroesophageal reflux disease before and after sphinct

73 shown to be a safe and effective therapy for gastroesophageal reflux disease, but its effect on the L

74 Symptoms frequently mimic those of gastroesophageal reflux disease, but the diseases are di

75 iteria consisted of a confirmed diagnosis of gastroesophageal reflux disease by an abnormal esophagea

76 , screening 50-year-old men with symptoms of gastroesophageal reflux disease by Cytosponge is cost ef

77 emerging disease that is distinguished from gastroesophageal reflux disease by the expression of a u

78 ished before their place in the treatment of gastroesophageal reflux disease can be determined.

79 suppression, have been confirmed in EoE and gastroesophageal reflux disease cell cultures.

80 Risk factors include gastroesophageal reflux disease, central obesity, and sm

81 Gastroesophageal reflux disease complicated by Barrett e

82 Gastroesophageal reflux disease complicated by Barrett's

83 search into the use of these technologies in gastroesophageal reflux disease continues to accelerate,

84 95% confidence interval [CI]: 1.04-2.67) or gastroesophageal reflux disease controls (OR = 1.61; 95%

85 bjects with gastroesophageal reflux disease (gastroesophageal reflux disease controls, n = 1332), and

86 sing and treating chest pain associated with gastroesophageal reflux disease, correlates abnormal amb

87 terms: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

88 lowing: heartburn, regurgitation, dysphagia, gastroesophageal reflux disease, cough, aspiration, lary

89 esophageal mucosal injury, the diagnosis of gastroesophageal reflux disease currently rests on 24-ho

90 Early aggressive surgical treatment of gastroesophageal reflux disease decreases the rate of br

91 to estimate the risk of new chronic cough or gastroesophageal reflux disease diagnosis.

92 [4.0%]) was more frequently associated with gastroesophageal reflux disease, diarrhea, bloating, abd

93 Mild-to-moderate chronic tissue injury in gastroesophageal reflux disease differentially affects m

94 es for detailed drugs (lipid-lowering drugs, gastroesophageal reflux disease drugs, antihypertensive

95 ugs in 8 drug classes (lipid-lowering drugs, gastroesophageal reflux disease drugs, diabetes drugs, a

96 of diseases such as functional dyspepsia and gastroesophageal reflux disease (e.g. vomiting, disorder

97 ecome available in the last 2 years for many gastroesophageal reflux disease endotherapies, providing

98 l gastrointestinal complications of obesity: gastroesophageal reflux disease, erosive esophagitis, Ba

99 Most patients with gastroesophageal reflux disease experience symptomatic r

100 This issue provides a clinical overview of gastroesophageal reflux disease, focusing on diagnosis,

101 moving patients with a previous diagnosis of gastroesophageal reflux disease from analysis, patients

102 gus (n = 1059) with those from subjects with gastroesophageal reflux disease (gastroesophageal reflux

103 ars, 43.9% female), and patients with proven gastroesophageal reflux disease (GERD) (European heartbu

104 .1; 95% confidence interval [CI], 2.9-12.9), gastroesophageal reflux disease (GERD) (RR, 1.9; 95% CI,

105 ts approximately 2.3% to 8.3% of people with gastroesophageal reflux disease (GERD) and approximately

106 lin, leptin, and ghrelin are associated with gastroesophageal reflux disease (GERD) and Barrett's eso

107 We examined the incidence and predictors of gastroesophageal reflux disease (GERD) and dyspepsia and

108 and evaluate esophageal disorders, including gastroesophageal reflux disease (GERD) and eosinophilic

109 The potential association between gastroesophageal reflux disease (GERD) and extraesophage

110 Skinner to the understanding of gastroesophageal reflux disease (GERD) and its complicat

111 might represent an alternative treatment of gastroesophageal reflux disease (GERD) and may provide d

112 has enormous potential for the treatment of gastroesophageal reflux disease (GERD) and other esophag

113 The advent of the Montreal definition of gastroesophageal reflux disease (GERD) and the Rome III

114 agement of extraesophageal manifestations of gastroesophageal reflux disease (GERD) and to compare th

115 Whether inflammation of the cardia indicates gastroesophageal reflux disease (GERD) and/or is a manif

116 Lung transplant recipients with documented gastroesophageal reflux disease (GERD) are at increased

117 Current diagnostic tests for gastroesophageal reflux disease (GERD) are suboptimal an

118 hageal eosinophilia who were thought to have gastroesophageal reflux disease (GERD) but who did not r

119 Management of gastroesophageal reflux disease (GERD) commonly starts w

120 t clear why only a minority of patients with gastroesophageal reflux disease (GERD) develop Barrett's

121 .4)] were included; 70% had been treated for gastroesophageal reflux disease (GERD) during infancy.

122 However, gastroesophageal reflux disease (GERD) has remained the

123 surgery, highly variable rates of recurrent gastroesophageal reflux disease (GERD) have been reporte

124 The histologic changes associated with acute gastroesophageal reflux disease (GERD) have not been stu

125 The prevalence of gastroesophageal reflux disease (GERD) in Africa is not

126 The aim was to compare recurrence of gastroesophageal reflux disease (GERD) in children rando

127 RAs) are frequently used in the treatment of gastroesophageal reflux disease (GERD) in children; howe

128 ull-thickness plication for the treatment of gastroesophageal reflux disease (GERD) in comparison wit

129 n (TF) can decrease or eliminate features of gastroesophageal reflux disease (GERD) in some patients

130 There are few data on the prevalence of gastroesophageal reflux disease (GERD) in the United Sta

131 Gastroesophageal reflux disease (GERD) increases EAC ris

132 Gastroesophageal reflux disease (GERD) is a chronic diso

133 Gastroesophageal Reflux Disease (GERD) is a common chron

134 Gastroesophageal reflux disease (GERD) is a common comor

135 Gastroesophageal reflux disease (GERD) is a common diagn

136 Gastroesophageal reflux disease (GERD) is a common medic

137 Severe gastroesophageal reflux disease (GERD) is a lifelong pro

138 Gastroesophageal reflux disease (GERD) is a risk factor

139 It has been suggested that gastroesophageal reflux disease (GERD) is a risk factor

140 Gastroesophageal reflux disease (GERD) is a very common

141 Gastroesophageal reflux disease (GERD) is associated wit

142 Endoscopic management of gastroesophageal reflux disease (GERD) is being employed

143 Gastroesophageal reflux disease (GERD) is caused by gast

144 The pathogenesis of gastroesophageal reflux disease (GERD) is complex and in

145 hageal mucosal injury across the spectrum of gastroesophageal reflux disease (GERD) is controversial.

146 Gastroesophageal reflux disease (GERD) is defined by rec

147 As the economic burden of gastroesophageal reflux disease (GERD) is largely weight

148 illustrated by the Montreal classification, gastroesophageal reflux disease (GERD) is much more than

149 Gastroesophageal reflux disease (GERD) is prevalent worl

150 ump inhibitor (PPI) therapy in patients with gastroesophageal reflux disease (GERD) is reported in up

151 Gastroesophageal reflux disease (GERD) is the most commo

152 Gastroesophageal reflux disease (GERD) is the most preva

153 Gastroesophageal reflux disease (GERD) is the strongest

154 f Helicobacter pylori in the pathogenesis of gastroesophageal reflux disease (GERD) is unknown.

155 Exclusion criteria included symptoms of gastroesophageal reflux disease (GERD) more than once a

156 Many individuals with gastroesophageal reflux disease (GERD) never visit their

157 f an underlying acid peptic disorder such as gastroesophageal reflux disease (GERD) nor should it pre

158 is name, currently used for the treatment of gastroesophageal reflux disease (GERD) or completing Hel

159 Refractory gastroesophageal reflux disease (GERD) reduces quality o

160 Most patients with gastroesophageal reflux disease (GERD) report that stres

161 It has been speculated that gastroesophageal reflux disease (GERD) represents a risk

162 Gastroesophageal reflux disease (GERD) seems to increase

163 Erosive esophagitis (EE) is the part of gastroesophageal reflux disease (GERD) spectrum and may

164 has been developed for use in patients with gastroesophageal reflux disease (GERD) symptoms despite

165 discrepancy reflects a higher prevalence of gastroesophageal reflux disease (GERD) symptoms or a hig

166 assessed the utility of NBI in patients with gastroesophageal reflux disease (GERD) symptoms.

167 Patients with gastroesophageal reflux disease (GERD) who are not respo

168 phagus (cases) were matched to subjects with gastroesophageal reflux disease (GERD) without Barrett's

169 tailed critique of objective measurements of gastroesophageal reflux disease (GERD) would improve man

170 BS), 3.0; dyspepsia, 1.8; constipation, 3.9; gastroesophageal reflux disease (GERD), 9.7.

171 Gastroesophageal reflux disease (GERD), a condition comm

172 cluding Crohn disease (CrD), celiac disease, gastroesophageal reflux disease (GERD), and eosinophilic

173 frequency of irritable bowel syndrome (IBS), gastroesophageal reflux disease (GERD), and overactive b

174 e upper airways dysfunction syndrome (RUDS), gastroesophageal reflux disease (GERD), and rare cases o

175 rm use of PPIs for three common indications: gastroesophageal reflux disease (GERD), Barrett's esopha

176 ireflux surgery is an effective treatment of gastroesophageal reflux disease (GERD), but the durabili

177 sophagus has been proposed for patients with gastroesophageal reflux disease (GERD), but there is lit

178 eneral U.S. population and for patients with gastroesophageal reflux disease (GERD), diabetes mellitu

179 this study was to appraise the prevalence of gastroesophageal reflux disease (GERD), esophagitis, and

180 n several pathophysiological states, such as gastroesophageal reflux disease (GERD), functional dyspe

181 Gastroesophageal reflux disease (GERD), functional dyspe

182 The association of body mass index and gastroesophageal reflux disease (GERD), including its co

183 Barrett esophagus, a complication of gastroesophageal reflux disease (GERD), predisposes pati

184 ients, who had a previous fundoplication for gastroesophageal reflux disease (GERD), underwent reoper

185 ed the accuracy of frequency and duration of gastroesophageal reflux disease (GERD), using data from

186 Gastroesophageal reflux disease (GERD), which leads to a

187 Unlike gastroesophageal reflux disease (GERD), whose symptoms c

188 can individuals have a similar prevalence of gastroesophageal reflux disease (GERD), yet esophageal a

189 defined as a decrease of 50% or more in the Gastroesophageal Reflux Disease (GERD)-Health Related Qu

190 s for a range of medical disorders including gastroesophageal reflux disease (GERD).

191 only used in the diagnosis and management of gastroesophageal reflux disease (GERD).

192 ctional gastrointestinal disorders (FGD) and gastroesophageal reflux disease (GERD).

193 e existing endoscopy-based interventions for gastroesophageal reflux disease (GERD).

194 a significant increase in the prevalence of gastroesophageal reflux disease (GERD).

195 in the past year has centered on surgery for gastroesophageal reflux disease (GERD).

196 on atypical/extraesophageal manifestation of gastroesophageal reflux disease (GERD).

197 a novel device for the surgical treatment of gastroesophageal reflux disease (GERD).

198 s and many do not report typical symptoms of gastroesophageal reflux disease (GERD).

199 the relaxed EGJ was altered in patients with gastroesophageal reflux disease (GERD).

200 mptoms (URS) among patients with symptomatic gastroesophageal reflux disease (GERD).

201 halasia, eosinophilic esophagitis (EoE), and gastroesophageal reflux disease (GERD).

202 ) during gastric distention in patients with gastroesophageal reflux disease (GERD).

203 enewed interest in the surgical treatment of gastroesophageal reflux disease (GERD).

204 one combination vs omeprazole monotherapy in gastroesophageal reflux disease (GERD).

205 en fundoplication (CNF) for the treatment of gastroesophageal reflux disease (GERD).

206 dal anti-inflammatory drugs) and symptoms of gastroesophageal reflux disease (GERD).

207 urgical option for patients with early-stage gastroesophageal reflux disease (GERD).

208 procedure of choice for obese patients with gastroesophageal reflux disease (GERD).

209 y risk factors for both BE and EA is chronic gastroesophageal reflux disease (GERD).

210 responders and treatment-naive patients with gastroesophageal reflux disease (GERD).

211 n accurate method for diagnosing adults with gastroesophageal reflux disease (GERD).

212 cations in adults were dysphagia (70.1%) and gastroesophageal reflux disease (GERD)/heartburn (27.1%)

213 and safety in the treatment of patients with gastroesophageal reflux disease (GERD); similarly, lapar

214 We also included 10 patients with gastroesophageal reflux disease (GERD; age, 32-60 y; 7 w

215 n 2002 and 2005 were matched to persons with gastroesophageal reflux disease (GERD; n = 316) and to p

216 onitoring on therapy in patients with proven gastroesophageal reflux disease [GERD]), to document phy

217 ether patient-identified domains (dysphagia, gastroesophageal reflux disease [GERD], nausea/vomiting,

218 Gastroesophageal reflux disease (GORD) is a chronic and

219 For the gastric cardia, the contributions of gastroesophageal reflux disease, H. pylori infection, an

220 ith congestive heart failure, and those with gastroesophageal reflux disease had greater odds of havi

221 rm outcome of ARS in pediatric patients with gastroesophageal reflux disease have shown good to excel

222 months improved in patients with normal GE (Gastroesophageal Reflux Disease Health-Related Quality o

223 is a laryngeal symptom that can be caused by gastroesophageal reflux disease; however, treatment outc

224 atients included degenerative joint disease, gastroesophageal reflux disease, hypertension, urinary s

225 imary laparoscopic antireflux surgery due to gastroesophageal reflux disease in adults (>18 years).

226 BMI is associated with symptoms of gastroesophageal reflux disease in both normal-weight an

227 ed strong genetic correlations of BE/EA with gastroesophageal reflux disease in male individuals and

228 re of the height in meters - and symptoms of gastroesophageal reflux disease in persons of normal wei

229 related to the acidic environment caused by gastroesophageal reflux disease in the gastroesophageal

230 Gastroesophageal reflux disease is a common clinical pro

231 Gastroesophageal reflux disease is a highly prevalent ch

232 Gastroesophageal reflux disease is a highly prevalent di

233 Gastroesophageal reflux disease is a prevalent disorder

234 Gastroesophageal reflux disease is common in adults of a

235 integrated concept of the pathophysiology of gastroesophageal reflux disease is constructed.

236 alivary protective factors in patient s with gastroesophageal reflux disease is impaired.

237 of the lower esophagus epithelium related to gastroesophageal reflux disease, is the strongest known

238 the AGA Institute on "Endoscopic Therapy for Gastroesophageal Reflux Disease." It was approved by the

239 w endoscopic therapies have emerged to treat gastroesophageal reflux disease itself.

240 depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joi

241 depressive disorder, anxiety, hypertension, gastroesophageal reflux disease, malaise or fatigue, joi

242 ssue injury in the esophagus associated with gastroesophageal reflux disease may result in sensitizat

243 a diligent search for an esophageal etiology-gastroesophageal reflux disease, motility abnormalities,

244 itant chemical carcinogen treatment leads to gastroesophageal reflux disease, multilayered epithelium

245 nths after fundoplication for PPI-refractory gastroesophageal reflux disease (n = 14 270 degrees LPF

246 (n = 296 cases) were matched to persons with gastroesophageal reflux disease (n = 308) without Barret

247 ad EoE (n = 17), indeterminate EoE (n = 15), gastroesophageal reflux disease (n = 7), or normal esoph

248 With improved understanding of gastroesophageal reflux disease, newer developments in d

249 on airway disease, including rhinosinusitis, gastroesophageal reflux disease, obesity and dysfunction

250 esophageal sphincter (LES) in patients with gastroesophageal reflux disease often has a low resting

251 is (EoE) was historically distinguished from gastroesophageal reflux disease on the basis of histolog

252 ociated with esophageal eosinophilia such as gastroesophageal reflux disease or achalasia.

253 ceiving long-term proton pump inhibitors for gastroesophageal reflux disease or in patients with any

254 ated with EoE (or indeterminate EoE) but not gastroesophageal reflux disease or normal esophagus and

255 intravenous therapy in patients with severe gastroesophageal reflux disease or the Zollinger-Ellison

256 ans should not use FLIP findings to diagnose gastroesophageal reflux disease or to determine the nece

257 , including history of peptic ulcer disease, gastroesophageal reflux disease, or gastrointestinal ble

258 This article is a review of gastroesophageal reflux disease, other types of esophagi

259 Glasgow Coma Scale score <9 (p = .021), and gastroesophageal reflux disease (p = .033).

260 We randomly assigned 64 gastroesophageal reflux disease patients to radiofrequen

261 esents a new option for selected symptomatic gastroesophageal reflux disease patients who are intoler

262 Too much acid can lead to gastroesophageal reflux disease, peptic ulcer disease, a

263 5), and more had a >50% improvement in their gastroesophageal reflux disease quality of life score (n

264 Diagnosis of GERD was by means of the gastroesophageal reflux disease questionnaire (GERDQ) wh

265 This chapter reviews the biology of gastroesophageal reflux disease, relating pathophysiolog

266 Endoscopic therapies for gastroesophageal reflux disease represent a minimally in

267 ted with a relatively high rate of recurrent gastroesophageal reflux disease requiring treatment, dim

268 Nausea related to gastroesophageal reflux disease resolves or is markedly

269 A possible therapy for gastroesophageal reflux disease should hinder gastroesop

270 premorbid prevalence of anxiety, headaches, gastroesophageal reflux disease, sleep apnea, and infect

271 nic nonsteroidal anti-inflammatory drug use, gastroesophageal reflux disease, smoking, constipation,

272 ministered a modified version of a validated gastroesophageal reflux disease-specific QOL tool to pat

273 Quality of life, measured by the gastroesophageal reflux disease-specific QOL tool, and r

274 Endoscopic findings related to gastroesophageal reflux disease such as esophagitis and

275 44 patients (52%) had objective findings of gastroesophageal reflux disease, such as esophagitis.

276 PRACTICE ADVICE 4: Patients with complicated gastroesophageal reflux disease, such as those with a hi

277 Symptoms improved in group A, with the Gastroesophageal Reflux Disease Symptom Assessment Scale

278 uency energy delivery significantly improved gastroesophageal reflux disease symptoms and quality of

279 racticed, its value in patients with chronic gastroesophageal reflux disease symptoms is of unproven

280 ng upper endoscopy for patients with chronic gastroesophageal reflux disease symptoms to assess for B

281 men in the United Kingdom with histories of gastroesophageal reflux disease symptoms, assuming the p

282 ost commonly occurs in patients with chronic gastroesophageal reflux disease that involves recurring

283 ier function, is a characteristic finding of gastroesophageal reflux disease that is also found in ob

284 Triggered by gastroesophageal reflux disease, the origin of this meta

285 ic conditions (hypertension, hyperlipidemia, gastroesophageal reflux disease, thyroid disease, diabet

286 inistration recently cleared new endoluminal gastroesophageal reflux disease treatments; however, no

287 The history of gastroesophageal reflux disease was highly prevalent in

288 Gastroesophageal reflux disease was identified as an imp

289 De novo gastroesophageal reflux disease was reported in 43.8%.

290 atic treatment of nocturnal heartburn due to gastroesophageal reflux disease, was approved by the US

291 bial flora, the IL-18 signaling pathway, and gastroesophageal reflux disease were among the causal fa

292 Markers of gastroesophageal reflux disease were compared between gr

293 screening ages for patients with symptomatic gastroesophageal reflux disease were older (58 for men a

294 as chronic sinusitis, allergic rhinitis, and gastroesophageal reflux disease were only associated wit

295 all publications relating to both asthma and gastroesophageal reflux disease were retrieved.

296 nflammation in squamous epithelium caused by gastroesophageal reflux disease, whereas intestinal meta

297 Except for gastroesophageal reflux disease, which showed a higher r

298 Patients with gastroesophageal reflux disease who have a partial respo

299 for 5.2 million visits annually, followed by gastroesophageal reflux disease, with 4.5 million visits

300 l adenocarcinoma (BEAC) is a complication of gastroesophageal reflux disease, with no effective chemo